Company Long-Term Loans and Borrowings: medicinova.com (MNOV)

Public company logo of MediciNova (MNOV)

MediciNova, Inc. (MNOV) develops advanced small molecules to combat asthma and severe brain pathologies by suppressing cellular inflammation. An efficient global warehouse network ensures the seamless delivery of drugs, maintaining high profitability. The price action vector available for analysis on GURU.Markets is fixed at 0.00. MediciNova, Inc. (MNOV) is betting on licensing agreements and partnerships, deliberately avoiding mergers and acquisitions.

MNOV MediciNova Inc. Company Long-Term Debts (07/04/2022 - 10/31/2026)

Summary analytical data breakdowns for MediciNova (MNOV)

- market price and analyst price targets:
Stock Price MediciNova Inc.|MNOV - Price Target Chart
- company stock exchange capitalization indicators:
Market Value MediciNova|MNOV - Total Company Value
- book capitalization information:
Accounting Value per Share MediciNova|MNOV - Book Capitalization|Market Capitalization to Book Value Ratio medicinova.com|MNOV - Cumulative Company Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio MediciNova, Inc.|MNOV - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio MediciNova Inc.|MNOV - Company Aggregate Debts|Debts to Book Value MediciNova|MNOV - Company Long-Term Liabilities|Company Short-Term Debts MediciNova|Intermediate Coverage Ratio medicinova.com
- earnings and multiples data:
MNOV - Company Net Income
Summary company analytics:MediciNova, Inc.
Brand item of MediciNova, Inc.

This indicator measures the aggregate of credit obligations with maturities exceeding one year, allowing for an assessment of the liability structure's stability and the risks of interest overpayments during refinancing. By analyzing the trajectory of the business's long-term debt capital, an investor can determine whether there is sufficient financial leverage to develop the MediciNova, Inc. (MNOV) biopharmaceutical ecosystem around the MN-166 molecule without risking a loss of solvency.

Competitor analysis for MediciNova, Inc.

Company Long-Term Debts jazzpharma.com JAZZ|CYTK - Company Long-Term Debt|Company Long-Term Loans and Borrowings PTCT (PTC Therapeutics Inc)|Scholar Rock Corp (SRRK) - Company Long-Term Debt|Company Long-Term Liabilities Centessa Corp|DYN (Dyne Therapeutics, Inc.) - Company Long-Term Debts|Company Long-Term Debts edgewisetx.com|Company Long-Term Liabilities RAPP (Rapport Therapeutics)|ALMS (Alumis Inc) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Kempharm ZVRA|CTNM: Company Long-Term Indebtedness|Larimar Therapeutics - Company Long-Term Debts|Long-Term Debt Capricor Therapeutics|TRDA (Entrada Therapeutics, Inc.) - Company Long-Term Liabilities|Channel Therapeutics Inc. (PTHS) - Company Long-Term Debts|Company Long-Term Debt Serina|BTAI: Company Long-Term Loans and Borrowings|Company Long-Term Debt ProMIS Neurosciences (PMN)|APUS - Long-Term Debt|Company Long-Term Debt AEON Biopharma, Inc. AEON|NLS Pharmaceutics Ltd. - Company Long-Term Debt|BNOX - Company Long-Term Debt|Long-Term Debt FSD Pharma, Inc.|RETA: Company Long-Term Debts